Drugs / mRNA-0184
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06655870 | Oct 2024 → Jun 2026 overdue | — | ModernaTX, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06243770 | Feb 2024 → Jun 2025 | — | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05659264 | Dec 2022 → Dec 2024 | heart failure | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-0184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05659264 ↗ |
| Route | Intravenous | “intravenous (IV) infusion” NCT05659264 ↗ |